EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System (Evolution Stent System) for the Treatment of a De Novo Atherosclerotic Lesion.
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms EVOLVE
- Sponsors Boston Scientific Corporation
- 01 May 2016 Status changed from active, no longer recruiting to completed.
- 19 May 2015 Long term data published in the Boston Scientific Corporation media release.
- 21 May 2014 Positive 3-year follow-up data have been published in a Boston Scientific media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History